Insider ownership of Retrophin, Inc.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
|FOF Cohen & Steers Closed-End Opportunity Fund, Inc.||NYSE > Finance > Closed-End Fund - Equity||139.26%|
|ACIU AC Immune SA||NASDAQ > Health Care > Major Pharmaceuticals||139.80%|
|BH Biglari Holdings Inc.||NYSE > Consumer Services > Restaurants||141.24%|
|FNJN Finjan Holdings, Inc.||NASDAQ > Miscellaneous > Multi-Sector Companies||143.04%|
|AST Asterias Biotherapeutics, Inc.||NYSEMKT > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||143.39%|
|GLBL TerraForm Global, Inc.||NASDAQ > Public Utilities > Electric Utilities: Central||143.65%|
|RTRX Retrophin, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||143.96%|
|EMITF Elbit Imaging Ltd.||NASDAQ > Consumer Services > Building operators||8,567.32%|
|ARWR Arrowhead Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||9,838.97%|
|KALV KalVista Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||10,692.86%|
|ACAD ACADIA Pharmaceuticals Inc.||NASDAQ > Health Care > Major Pharmaceuticals||14,131.15%|
|CYAD Celyad SA||NASDAQ > Health Care > Major Pharmaceuticals||149,734.18%|
|VLRX Valeritas Holdings, Inc.||NASDAQ > Health Care > Medical/Dental Instruments||246,776.16%|